title: HLA class II-mediated death is induced via Fas/Fas ligand interactions in human splenic B lymphocytes.
abstract: HLA class II molecules, expressed on the surface of antigen-presenting cells, are responsible for the presentation of antigen-derived peptides to CD4+ helper T lymphocytes. Signaling via these molecules initiates the generation of second messengers leading to programed cell death (PCD) of activated B lymphocytes. The present study examined the mechanism of HLA class II-mediated apoptosis and describes the essential role of the molecule Fas and its ligand (FasL). FasL was expressed in B lymphocytes after stimulation via HLA class II or with phorbol esters. Expression of FasL protein was significantly increased in 50% of B lymphocytes after stimulation via HLA class II, and the level of FasL mRNA was also increased either by activation with phorbol esters and ionomycin or by signaling via HLA class II. Although HLA class II signaling did not change the expression of the Fas molecule, it did lead to increased sensitivity to Fas-mediated apoptosis. The crucial role of Fas/FasL interactions was confirmed by the absence of cell death via HLA class II in B cells lacking Fas expression, and by the significant inhibition of HLA class II-mediated apoptosis in the presence of either an antagonistic anti-Fas or anti-FasL antibody. These data demonstrate FasL expression on activated human B lymphocytes and support the idea that antigen presentation could contribute to the regulation of lymphocyte populations via Fas and FasL interactions.
authors.affiliation: INSERM U396, Institut Biomédical des Cordeliers, Paris, France.
authors.forename: J P
authors.initials: JP
authors.lastname: Truman
authors.forename: C
authors.initials: C
authors.lastname: Choqueux
authors.forename: J
authors.initials: J
authors.lastname: Tschopp
authors.forename: J
authors.initials: J
authors.lastname: Vedrenne
authors.forename: F
authors.initials: F
authors.lastname: Le Deist
authors.forename: D
authors.initials: D
authors.lastname: Charron
authors.forename: N
authors.initials: N
authors.lastname: Mooney
mesh_terms: D019138:Antibodies, Blocking / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D017209:Apoptosis / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology* / Q000378:metabolism*; D053222:Fas Ligand Protein; D000949:Histocompatibility Antigens Class II / Q000502:physiology*; D006801:Humans; D008024:Ligands; D008213:Lymphocyte Activation; D008562:Membrane Glycoproteins / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D012333:RNA, Messenger / Q000096:biosynthesis; D015398:Signal Transduction / Q000276:immunology; D013154:Spleen / Q000166:cytology / Q000276:immunology; D019014:fas Receptor / Q000276:immunology / Q000378:metabolism*
chemical_list: D019138:Antibodies, Blocking; D000911:Antibodies, Monoclonal; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D000949:Histocompatibility Antigens Class II; D008024:Ligands; D008562:Membrane Glycoproteins; D012333:RNA, Messenger; D019014:fas Receptor